[Genetic Counselor]

For an individual confirmed to carry a BRCA2 mutation, a structured, lifelong surveillance plan should be established in coordination with a clinical geneticist, oncologist, and gynaecologist, since the elevated risk applies to multiple organ systems and not breast tissue alone.

*For breast cancer surveillance, clinical breast examination should be performed every six to twelve months starting at age twenty-five, alongside annual breast magnetic resonance imaging beginning at age twenty-five, with annual mammography added from age thirty onward, and both imaging modalities are typically alternated every six months so that the breast tissue is monitored twice a year in total. Breast self-awareness training should also be provided so that any new lump, skin change, or nipple discharge is reported promptly rather than waiting for the next scheduled screening.
*For ovarian cancer, routine screening using transvaginal ultrasound and the blood marker cancer antigen 125 has not been shown to reliably detect ovarian cancer at an early stage, so the primary proactive step recommended is risk-reducing bilateral salpingo-oophorectomy between the ages of forty and forty-five or after childbearing is complete, since no effective early detection tool currently exists for this cancer type. Because BRCA2 mutations also raise the lifetime risk of pancreatic cancer, individuals with a family history of pancreatic cancer should discuss annual surveillance using magnetic resonance imaging or endoscopic ultrasound with a specialist, typically starting around age fifty or ten years before the earliest pancreatic cancer diagnosis in the family.
*Men who carry a BRCA2 mutation should begin prostate-specific antigen based prostate cancer screening earlier than the general population, generally from the age of forty years, given the documented increase in prostate cancer risk and aggressiveness associated with this gene.
*Skin examinations for melanoma should also be discussed with a dermatologist given the associated risk. Alongside clinical surveillance, lifestyle measures that support overall risk reduction include maintaining a healthy body weight, limiting alcohol consumption, avoiding tobacco use, and staying physically active, since these factors influence overall cancer risk even though they do not eliminate the genetic risk itself.

Finally, genetic counseling should be revisited periodically, since surveillance guidelines are updated as research evolves, and family planning discussions, including options such as preimplantation genetic testing, should be raised with a fertility specialist if the individual is considering having children.

[Genetic Counselor]

While BRCA1 and BRCA2 remain the genes most strongly and most commonly associated with Hereditary Breast and Ovarian Cancer syndrome, they do not account for all cases of inherited breast and ovarian cancer risk within a family, which is why a broader multigene cancer panel is now frequently recommended instead of testing these two genes in isolation.

Clinical experience and large-scale studies have shown that a meaningful proportion of individuals who meet the clinical criteria for hereditary breast and ovarian cancer testing, yet test negative for BRCA1 and BRCA2, go on to be found positive for a mutation in another moderate- or high-risk gene when a panel is used, including PALB2, CHEK2, ATM, RAD51C, RAD51D, TP53, PTEN, STK11, and CDH1, among others. Each of these genes carries its own distinct pattern and magnitude of cancer risk. For example, PALB2 mutations confer a breast cancer risk that approaches the risk seen with BRCA2 mutations, RAD51C and RAD51D mutations are more specifically linked to elevated ovarian cancer risk with a comparatively lower breast cancer risk, TP53 mutations are associated with Li-Fraumeni syndrome and a very broad multi-organ cancer risk profile beginning in childhood, and CDH1 mutations are linked to hereditary diffuse gastric cancer alongside lobular breast cancer risk. Because the clinical presentation of families carrying mutations in these different genes can overlap substantially with families carrying BRCA1 or BRCA2 mutations, relying on BRCA1 and BRCA2 testing alone risks missing a hereditary cancer diagnosis, which in turn means the individual would not be offered the gene-specific surveillance, risk-reducing surgery timing, or targeted treatment options that would otherwise be available to them.

A multigene panel also offers practical and financial efficiency, since testing several relevant genes simultaneously using a single blood or saliva sample is generally more cost-effective and faster than testing genes one at a time in succession. However, panel testing also carries the added complexity of a higher chance of identifying a variant of uncertain significance, meaning a genetic change whose relationship to cancer risk is not yet clearly established, which requires careful pre-test and post-test genetic counselling so the individual understands that such a result does not currently change medical management. In the Indian context, where population-specific mutation spectrum data is still being established, panel testing is particularly useful because it captures a wider range of possible pathogenic mutations that may not yet be as well characterised in local Ashkenazi-style founder mutation databases, thereby improving diagnostic yield for Indian patients and families being evaluated for Hereditary Breast and Ovarian Cancer syndrome.

[Genetic Counselor]

For an individual confirmed to carry a BRCA1 mutation, a structured, lifelong surveillance plan should be established in coordination with a clinical geneticist, oncologist, and gynaecologist, since the elevated risk applies to multiple organ systems and not breast tissue alone.

*For breast cancer surveillance, clinical breast examination should be performed every six to twelve months starting at age twenty-five, alongside annual breast magnetic resonance imaging beginning at age twenty-five, with annual mammography added from age thirty onward, and both imaging modalities are typically alternated every six months so that the breast tissue is monitored twice a year in total.
*Breast self-awareness training should also be provided so that any new lump, skin change, or nipple discharge is reported promptly rather than waiting for the next scheduled screening.
*For ovarian cancer, routine screening using transvaginal ultrasound and the blood marker cancer antigen 125 has not been shown to reliably detect ovarian cancer at an early stage, so the primary proactive step recommended is risk-reducing bilateral salpingo-oophorectomy between the ages of thirty-five and forty or after childbearing is complete, this window being earlier than for BRCA2 carriers because BRCA1 mutations are associated with a higher and earlier-onset lifetime ovarian cancer risk, since no effective early detection tool currently exists for this cancer type. *Pancreatic cancer surveillance is not routinely recommended for BRCA1 carriers, since the association between BRCA1 mutations and pancreatic cancer risk is weaker and less consistently established compared to BRCA2, though individuals with a strong family history of pancreatic cancer specifically should still discuss surveillance options with a specialist.
*Men who carry a BRCA1 mutation have a smaller increase in prostate cancer risk compared to BRCA2 carriers, so prostate-specific antigen based prostate cancer screening is generally discussed from around age forty-five, in line with general moderate-risk guidance, though this should be individualised based on family history.
*Skin examinations for melanoma should still be discussed with a dermatologist, though the association with BRCA1 is not strongly established. Alongside clinical surveillance, lifestyle measures that support overall risk reduction include maintaining a healthy body weight, limiting alcohol consumption, avoiding tobacco use, and staying physically active, since these factors influence overall cancer risk even though they do not eliminate the genetic risk itself.
*Finally, genetic counseling should be revisited periodically, since surveillance guidelines are updated as research evolves, and family planning discussions, including options such as preimplantation genetic testing, should be raised with a fertility specialist if the individual is considering having children.

[Genetic Counselor]

Yes. Genetic testing is one of the most useful tools for finding an underlying cause of developmental delay when other evaluations haven’t provided an answer, and it can guide more targeted care going forward.

[Genetic Counselor]

Your care team will help you understand what the result means, what steps come next, and connect you with relevant specialists if needed. Genetic counselors are also there to support you through the emotional aspects of a diagnosis, not just the medical details.

[Genetic Counselor]

Genetic counseling focuses specifically on understanding inheritance, risk, and the implications of genetic information for you and your family, often involving a detailed family history review. A regular medical consultation typically focuses on diagnosing and treating a specific health issue.

[Genetic Counselor]

Not necessarily. While some patients are referred by their doctor, you can also directly book a consultation with a clinical geneticist if you have concerns about your health or family history.

[Genetic Counselor]

Genetic testing is useful for both. Beyond rare diseases, it also plays a role in common conditions like certain cancers, heart disease, and pregnancy-related risks, helping guide prevention and treatment decisions.

[Genetic Counselor]

Genetic counseling and testing are generally recommended after two or more pregnancy losses, though evaluation may begin earlier if there is a known family history of a genetic condition, if the couple is from a background with a higher carrier frequency for certain inherited disorders, if there is consanguinity, or if a prior pregnancy loss showed a chromosomal abnormality on testing. Genetic counseling helps the couple understand which tests are appropriate for their specific situation, what the results can and cannot explain, and what the implications are for future pregnancies including options such as preimplantation genetic testing during in vitro fertilization, if relevant.

[Genetic Counselor]

A balanced translocation occurs when pieces of two chromosomes break off and swap places. If the total genetic material is complete and correctly arranged, the carrier parent is typically healthy with no symptoms, the rearrangement only becomes apparent when it affects reproduction.

The problem arises during the formation of eggs or sperm. When chromosomes divide, the embryo can end up with an unbalanced amount of genetic material, extra or missing pieces, even though the parent’s own chromosome set is complete. This unbalanced combination is often incompatible with a viable pregnancy, leading to miscarriage.

Balanced translocations are found in a small percentage of couples with recurrent pregnancy loss, which is why parental karyotyping is a standard part of the workup even when both partners appear completely healthy.

Couples found to carry a balanced translocation have several options to consider, and the right path depends on their personal preferences, prior pregnancy history, and access to reproductive technology:

*Natural conception with prenatal diagnosis, using chorionic villus sampling or amniocentesis in a future pregnancy to check the chromosomal status of the fetus
*In vitro fertilization with preimplantation genetic testing for structural rearrangements, which allows embryos to be tested before transfer, reducing the chance of transferring an embryo with an unbalanced chromosomal pattern
*Use of donor eggs or sperm, in select circumstances
*Continued attempts at natural conception without additional testing, which remains a valid choice for some couples, since many carriers of balanced translocations do go on to have successful pregnancies over time

A genetic counselor can walk the couple through the actual chance of an unbalanced outcome specific to their translocation, since this varies considerably depending on which chromosomes are involved.

[Genetic Counselor]

Recurrent pregnancy loss is often multifactorial. Key contributors include:

*Antiphospholipid syndrome, an autoimmune condition affecting blood clotting, diagnosed through specific antibody blood tests
*Uterine structural abnormalities, such as a uterine septum, fibroids, or scarring, evaluated using ultrasound, hysteroscopy, or magnetic resonance imaging
*Endocrine factors, including uncontrolled thyroid dysfunction, poorly controlled diabetes, and luteal phase issues
*Advanced maternal age, which increases the likelihood of chromosomally abnormal eggs
Lifestyle factors, such as smoking, significant obesity, and heavy alcohol use

It is important to note that in roughly 50% of cases, a definitive cause is not found despite thorough evaluation, which can be difficult for couples to hear but does not rule out a healthy future pregnancy.

[Genetic Counselor]

The genetic workup usually happens in two parts: testing the couple, and testing the pregnancy tissue if a loss occurs.

For the couple:

*Parental karyotyping for both partners, to check for balanced chromosomal rearrangements (such as balanced translocations or inversions) that don’t affect the parent’s health but can cause repeated miscarriages
*Carrier screening for specific inherited conditions if there’s a relevant family history

For the pregnancy tissue (if available):

*Products of Conception (POC) testing, using karyotyping or microarray analysis, to check whether the loss was due to a chromosomal abnormality in the embryo itself

Additional non-genetic tests that are recommended only in certain circumstances include:
*Antiphospholipid antibody testing: only if clinical criteria for antiphospholipid syndrome are met (generally three or more losses, or a personal clotting history)
*Thyroid-stimulating hormone: for patients with risk factors, a euploid (chromosomally normal) miscarriage, or no tissue testing done
*Endometrial biopsy for chronic endometritis, and sperm DNA fragmentation testing: both only when the recurrent pregnancy loss is otherwise unexplained or infertility coexists

[Genetic Counselor]

Recurrent Pregnancy Loss (RPL) is generally defined as the spontaneous loss of two or more pregnancy excluding confirmed molar or ectopic pregnancies. A pregnancy confirmed only by a urine or blood hCG test or biochemical tests counts, an ultrasound or tissue confirmation isn’t required, since access to early pregnancy ultrasound varies widely.
Genetic evaluation becomes relevant because chromosomal and genetic factors are among the most common identifiable causes, particularly after the second loss.

The testing is used to be recommended after two or more consecutive miscarriages, however newer guidelines recommends to not waits till third loss and start the work up from second pregnancy onwards.

[Genetic Counselor]

A positive result doesn’t mean cancer is present; it means the lifetime risk is significantly elevated, so management is proactive rather than reactive. The main options discussed with the care team are:

*Prophylactic (preventive) total gastrectomy – surgical removal of the stomach before cancer develops, which offers the most definitive risk reduction and is often recommended in adulthood, typically after the age of 20 years, once organ growth is complete
*Enhanced endoscopic surveillance – for those not ready for surgery, using specialized biopsy protocols, since standard endoscopy can miss diffuse-type cancer
*Women with CDH1 mutations are also usually advised to start enhanced breast screening due to the associated lobular breast cancer risk

The right path depends on age, family history severity, personal preference, and a detailed discussion with a clinical geneticist and surgical oncologist – it’s a shared decision, not an automatic surgical mandate.

[Genetic Counselor]

Testing is typically considered when a family shows one or more of these patterns:

*Two or more cases of gastric cancer in close relatives, with at least one being diffuse-type, at any age
*One case of diffuse-type gastric cancer diagnosed before age 40, even without other affected relatives
*A personal or family history of diffuse gastric cancer together with a specific type of breast cancer called lobular breast cancer (CDH1 gene mutations also raise this risk in women)
*A family history of cleft lip or cleft palate alongside diffuse gastric cancer (seen in some families with CDH1 gene mutations)
A genetic counselor can assess the specific family pattern and advise whether testing for the CDH1 or CTNNA1 genes is appropriate, since not every family history needs testing.

[Author]

Posts